Evoke Pharma Inc., a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Service LLC, an independent provider of global commercial services to the life science industry, announced an extension of their agreement. The companies will continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the United States through the end of 2026.
A look at upcoming PDUFA dates for the U.S. Food and Drug Administration, including Viela Bio’s inebilizumab for NMOSD.
The collaboration will utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Evoke Pharma Inc.’s Gimoti in the United States.
Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.
Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.
Allergan struck a $200 million deal to snag Motus Therapeutics in an effort to shore up its gastrointestinal therapies.